Skip to main content
Figure 2 | Journal of Translational Medicine

Figure 2

From: VEGF-A isoform modulation in an preclinical TNBS model of ulcerative colitis: protective effects of a VEGF164b therapy

Figure 2

Assessment of disease progression in the TNBS model of UC. Disease activity index (DAI) was determined in control, Ad5-CMV-rVEGF164b, TNBS, and TNBS + Ad5-CMV-rVEGF164b treated mice. * denotes significant differences between treated and untreated TNBS mice on that day. (A); n = 5. Colon length to weight ratio was determined in control, Ad5-CMV-rVEGF164b, TNBS, and TNBS + Ad5-CMV-rVEGF164b mice at day 3 (B) and day 21 (C) of disease. MPO assay results at day 3 (D) and day 21 (E) in disease were determined from control, Ad5-CMV-rVEGF164b, TNBS, and TNBS + Ad5-CMV-rVEGF164b colons; n = 5. Shown are *p < 0.05, **p < 0.005.

Back to article page